Clinical Cases in Pharmacology Clinical Cases  ·  Urology Vol. I  ·  General Urology  ·  Reaching for the Antibiotic Anyway, After the Trial That Said Not To
Urology Vol. I, Case 0008 — General Urology

Reaching for the Antibiotic Anyway, After the Trial That Said Not To

His cultures are negative and the standard first-line combination has already been tested against placebo and lost. The debate is whether to keep reaching for it out of habit or build a plan around what actually seems to be driving his pain.

Abbreviations, terms, and other agents mentioned in this case CP/CPPS — chronic prostatitis / chronic pelvic pain syndrome  ·  NIH category III — National Institutes of Health prostatitis classification, category III  ·  UPOINT — Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness — a phenotyping framework
Presentation

M.S., 34, started a new software engineering job eight months ago — a promotion he'd wanted for years, with longer hours and a level of pressure he says he underestimated. His perineal and pelvic pain began roughly a month into the new role and has persisted for eight months since, accompanied by irritative urinary symptoms he describes as urgency without much frequency. Three separate urine cultures, drawn at different points during flares, have all come back negative. He has been given two prior courses of ciprofloxacin by different providers, each without meaningful improvement.

On exam, his pelvic floor musculature is notably tender to palpation, well beyond the prostate itself, and he readily connects his worst flares to his highest-stress weeks at work — a pattern he brought up himself before being asked about it, describing a near one-to-one correspondence between a bad sprint at work and a bad week physically that has held for as long as he's been tracking it, which is itself a finding rather than just context. He has no fever, no hematuria, and no structural abnormality on prior imaging. He has started keeping a rough log of his own — flare severity against sprint deadlines — and brought it to today's visit unprompted, a level of self-tracking that says something about how much this has begun to structure his daily life outside of work as well as inside it. He is, understandably, frustrated that two courses of antibiotics for an infection nobody has ever actually documented haven't helped, and is now asking whether there's a different way to think about this. He has no significant past medical history, exercises regularly when his schedule allows, and describes himself as generally even-tempered outside of this specific problem, which is part of why the connection to his work stress struck him as worth mentioning rather than something to downplay.

M.S. · 34 Index Case
History
8 months pelvic/perineal pain, irritative urinary symptoms
Cultures
Negative x3, drawn during separate flares
Prior treatment
2 courses of ciprofloxacin, no meaningful improvement
Exam finding
Marked pelvic floor tenderness
Symptom pattern
Flares track closely with work-stress weeks
Imaging/structural workup
Unremarkable
Consultation

What the negative trial already answered

Clinical Pharmacologist Opening

Alexander and colleagues actually tested this exact question in 2004 — ciprofloxacin, tamsulosin, and the combination, all against placebo, in men with CP/CPPS. None outperformed placebo. He's already had two courses of the drug the trial found doesn't work, with no positive culture to justify a third. Continuing down that path isn't a reasonable trial, it's repeating an experiment that's already been run.

Urologist Response

I'd hold that a little more loosely than a closed question. Standard culture technique misses fastidious or intracellular organisms, and plenty of clinicians have seen genuine symptom improvement on antibiotics in culture-negative men that one trial doesn't fully explain away. Alexander also enrolled a refractory, heavily pretreated group — a mean of 6.2 years of symptoms — and he's eight months in, which is not obviously the same patient. I'm not proposing a third identical course — but I wouldn't call the infection hypothesis dead just because this specific trial came back negative.

He's already had two negative-culture antibiotic courses fail. At what point does "the trial doesn't capture everything" stop being a reason to try again on the same hypothesis, in this particular patient?

Pain Medicine Specialist Final

That's the right question, and it points away from another antibiotic trial entirely. He has two specific, actual findings in front of us — marked pelvic floor tenderness and flares that track his own reported stress — that map directly onto two UPOINT domains. That framework hasn't been tested head-to-head against usual care, but it's built from what's actually true about him, not a population-average guess about an infection nobody has ever confirmed. I'd treat the findings in front of us rather than run a third course aimed at a hypothesis two prior courses have already weighed against.

Regimen selected
Amitriptyline (low-dose) — Started
Tricyclic Antidepressant · 10mg nightly, targeting the tenderness/neurologic domain
Matched to his marked pelvic floor tenderness on exam, a specific UPOINT-domain finding rather than a population-average guess.
Ciprofloxacin — Ruled Out
Fluoroquinolone · Considered, not repeated
Alexander 2004 found no benefit over placebo; already failed twice in this patient with no positive culture to justify a third course.
Tamsulosin — Ruled Out
Alpha-1 Adrenergic Antagonist · Considered, not started
Same trial found no benefit over placebo, alone or combined with ciprofloxacin, in this presentation.
Where this was left

Agreed: start low-dose amitriptyline targeting the tenderness/neurologic domain, refer for pelvic floor physical therapy, and offer a brief counseling referral for the stress-correlated flare pattern he described himself — a UPOINT-directed plan rather than a third antibiotic course.

Not agreed: whether to send a more sensitive expressed-prostatic-secretion or post-massage urine culture before fully setting aside the infection hypothesis. The urologist wants that step covered before closing the door on it; the pharmacologist thinks it adds delay without changing management given the trial data already in hand.

Educational content only — a composite teaching case, not a real patient encounter or a substitute for clinical guidance. About These Cases →